Sign In
Regional Medical Lab
Test Directory


SARS-CoV-2 IgG, Nucleocapsid

Order Name CoV2 IgG NucCap
Test Number: 6901550
Revision Date 04/02/2021
Test Name Methodology LOINC Code
SARS-CoV-2 IgG, Nucleocapsid
Chemiluminescent Micropartical Immunoassay 94507-1 
Specimen Specimen Volume (min) Specimen Type Specimen Container Transport Environment
Preferred 2 mL (0.5 mL) Serum Clot Activator SST Refrigerated
Instructions Stability: Ambient 2 days; Refrigerated 7 days; Freeze if testing will be delayed more than 7 days
Testing Schedule Mon-Fri 
Expected TAT 1-2 Days  
Clinical Use RML has initiated two assays for the semi-quantitative detection of IgG antibodies to the COVID 19 nucleocapsid and a second to the COVID 19 spike protein. The IgG antibodies to the nucleocapsid can only come about following a SARS-CoV-2 infection. IgG antibodies to the spike protein will follow an infection and/or a vaccination with a spike initiating vaccine. The assays will be valuable in discerning as to whether the patient has or has not had a COVID 19 infection or a vaccination. The semi-quantitative values will be important to determine the degree of antibody activity in seroconversion as well as following the status of the levels of antibody activity over time. They will be available in two formats. One is the COVID 19 IgG anti-spike and the other is COVID 19 IgG anti-nucleocapsid. The results will be reported as a relative value (i.e. positive or negative) as well as a semi-quantitative value.

To view FDA required fact sheets about COVID-19 testing, Click Here. 
Notes Testing for IgG Nucleocapsid antibody to the novel Coronavirus (SARS-CoV-2/COVID-19) performed at RML core lab.
CPT Code(s) 86769
Lab Section Chemistry